Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Recent News

Potential Biomarkers for Renal Cell Carcinoma Studied
UCLA Kidney Donation Program: ‘Vouchers’ for Future Transplants
ESMO 2017: Cabozantinib Versus Sunitinib as Initial Targeted Therapy in Metastatic Renal Cell Carcinoma
ASTRO 2017: Combined High-Dose Radiation and Surgery for Renal Cell Carcinoma
ASTRO 2017: Can SABR Provide an Alternative to Surgery for Primary Renal Tumors in Metastatic Kidney Cancer?
ESMO 2017: Updated Data on Atezolizumab Plus Bevacizumab in Metastatic Renal Cell Carcinoma
ESMO 2017: Evaluating Multikinase Inhibitor Sequence in Advanced Renal Cell Carcinoma
ESMO 2017: Combination Therapy With Radium-223 in Metastatic Renal Cell Carcinoma With Bone Metastases
ESMO 2017: Rocapuldencel-T in Metastatic Renal Cell Carcinoma
ESMO 2017: Timing of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
ESMO 2017: Combination of Nivolumab and Ipilimumab in Advanced or Metastatic Kidney Cancer
Incidence of Kidney Cancer in California: Rising or Declining?
Association Between ctDNA Detection and Tumor Burden in Advanced Kidney Cancer
European Commission Approves Tivozanib in Treatment of Advanced Renal Cell Carcinoma
Neoadjuvant and Adjuvant Sunitinib in Untreated Renal Cell Carcinoma
Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
CM082 Plus Everolimus in Pretreated Metastatic Renal Cell Carcinoma
Ipilimumab Plus Nivolumab Combination Therapy for Metastatic Renal Cell Carcinoma
Epacadostat Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma
Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma
Genetic Profiling of Advanced Papillary Renal Cell Carcinoma
Treatment With Pazopanib in von Hippel-Lindau Disease
Surveillance Strategies After Surgery for Renal Cell Carcinoma
Integrating Immune Checkpoint Blockade Into Management Decisions in Kidney Cancer
ASCO 2017: Combination of Pazopanib and Pembrolizumab in Advanced Renal Cell Carcinoma
AUA 2017: Blue Light Cystoscopy for Detection of Bladder Cancer Recurrence
ASCO 2017: Alternate Schedule of Sunitinib in Metastatic Renal Cell Carcinoma
Phase III Trial to Compare First-Line Lenvatinib Combinations in Metastatic Renal Cell Carcinoma
ASCO 2017: Recurrence Score Results in High-Risk Patients With Renal Cell Carcinoma
ASCO 2017: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma
ASCO 2017: Atezolizumab Plus Bevacizumab in Metastatic Renal Cell Carcinoma
Durvalumab Granted Accelerated Approval in Urothelial Carcinoma
ASCO 2017: Treatment After Nephrectomy in Patients With Renal Cell Carcinoma
ASCO 2017: Avelumab and Axitinib in Untreated Renal Cell Carcinoma
Prognostic Model in Renal Cell Carcinoma After Nephrectomy